Literature DB >> 6928748

Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization.

A L Rassiga, H J Schwartz, W B Forman, E D Crum.   

Abstract

An anaphylactic episode occurred in a patient receiving cytarabine (Ara-C) for acute myeloid leukemia. Specific allergy of the patient to cytarabine was demonstrated in vivo by intradermal testing and in vitro by four-hour passive cutaneous anaphylaxis in guinea pigs. Desensitization to cytarabine was successfully performed. This case represents the first known report of both cytarabine anaphylaxis and densensitization, and provides immunologic evidence implicating an allergic reaction to cytarabine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6928748     DOI: 10.1001/archinte.140.3.425

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  Polyneuritis after HD Ara-C therapy for malignant lymphoma.

Authors:  L Montalbetti; G Brambilla Pisoni; G Trotti; M V Calloni
Journal:  Ital J Neurol Sci       Date:  1992-02

Review 2.  Hypersensitivity reactions from antineoplastic agents.

Authors:  R B Weiss; J R Baker
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 3.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

4.  Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report.

Authors:  Xia Yang; Wei Liu; Allie Lyons; Zaiwei Song; Suodi Zhai; Kai Hu
Journal:  Eur J Clin Pharmacol       Date:  2017-10-27       Impact factor: 2.953

5.  Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.

Authors:  Hui-Jen Tsai; Hui-Hua Hsiao; Ya-Ting Hsu; Yi-Chang Liu; Hsiao-Wen Kao; Ta-Chih Liu; Shih-Feng Cho; Xiaoxing Feng; Amanda Johnston; John S Bomalaski; Ming-Chung Kuo; Tsai-Yun Chen
Journal:  Cancer Med       Date:  2021-03-30       Impact factor: 4.452

6.  A desensitization protocol for delayed allergy to cytarabine: analysis of two cases.

Authors:  Marcello Albanesi; Paola Carluccio; Andrea Nico; Lucia Giliberti; Danilo Di Bona; Maria Filomena Caiaffa; Giorgina Specchia; Luigi Macchia
Journal:  Postepy Dermatol Alergol       Date:  2018-04-24       Impact factor: 1.837

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.